Skip to content

Diabetes Registry Graz for Biomarker Research

Diabetes Registry Graz for Biomarker Research

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05324488
Acronym
GIRO
Enrollment
2000
Registered
2022-04-12
Start date
2015-10-21
Completion date
2035-02-01
Last updated
2023-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adiposity, Type1diabetes, Type 2 Diabetes

Keywords

cohort study

Brief summary

The Diabetes registry for biomarker research Graz is a prospective cohort-study including subjects with type 1 and type 2 diabetes, rare types of diabetes, obesity and dyslipidemia, aiming to collect data, blood and urine samples of all subjects on an annual basis.

Detailed description

Obesity and diabetes represent probably the most challenging threat to public health in the 21st century. Despite well-controlled established cardiovascular risk factors, the residual risk in subjects with diabetes mellitus is significantly higher than the risk in those without the condition and it is well established that current risk prediction models for cardiovascular disease using established risk factors do not fully explain the future cardiovascular risk. Therefore, biomarker for better risk stratification are needed, in particular in subjects with diabetes mellitus. Prospective cohorts, meticulously clinically phenotyping subjects, regularly following them and collecting biomarker samples is one key approach for finding new biomarker panels, that are predictive of treatment response and future micro- and macrovascular complications. The Diabetes registry for Biomarker Research Graz was initiated in November 2015. Subjects with type 1 and type 2 diabetes, rare types of diabetes, obesity or dyslipidemia are recruited in the outpatient clinic for Diabetes, Lipid and Metabolic Disorders at the University Clinic Graz or in the Rehabilitation Center St. Radegund. As of September 2021, 1250 subjects are recruited. Blood and urine samples samples are collected at baseline and at annual follow up visits as well as data on medical history, diagnoses and medication.

Interventions

OTHERNo intervention

In this registry no intervention is carried out

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* 18 - 99 years * Informed consent has to be given in written form * At least one of the following diseases: * Type 1 diabetes * Type 2 diabetes * Type 3 diabetes * Maturity onset diabetes of young (MODY) * Late onset diabetes of the adult (LADA) * Adipositas (BMI \> 30kg/m2) * Lipid metabolism disorder

Exclusion criteria

* No written informed consent * No willingness to participate in this registry

Design outcomes

Primary

MeasureTime frameDescription
Biomarker identificationOver entire period of registry (20 years)Identification of biomarker panels that allow prediction of future micro- and macrovascular disease and events. Changes of these biomarkers over time in a selected, defined cohort will be reported.

Secondary

MeasureTime frameDescription
Biomarker validationOver entire period of registry (20 years)Validation of suggested biomarkers in the field of diabetes complications.

Countries

Austria

Contacts

Primary ContactCaren Sourij, MD
caren.sourij@medunigraz.at
Backup ContactHarald Sourij, MD
ha.sourij@medunigraz.at

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026